b'Monoclonal Antibodies Are Promising For Improving MM Survival Time HANGZHOU, CHINA Because multiple myelomaexclusivelyonhigh-risk Thelast20yearshaveremains incurable, therapies fordiseaseforwhompro-brought many more thera- the relapsed/refractory type arespectivetrialsarelim-peuticsformultiplemy- emerging and evolving rapidly. ited.Researcherssaid eloma (MM). theyaimedtoinduce Arecentreviewintheminimal residual disease AnnalsofHematology(MRD) negativity.2pointed out the standard first-line therapy for MMTheacademic,investigator-initiated,multi-consists of a three-drug induction regimen basedcenter, phase II trial enrolled patients with high-onimmunomodulatorydrugsandproteasomerisk NDMM (HRNDMM) defined by mandatory inhibitorscombinedwithautologousstemcellInternationalStagingSystemstageII/IIIcom-transplantation. However, MM remains incurable;bined with del17p, t(4;14), t(14;16) or more than therefore,therapiesforrelapsed/refractoryMMthree 1q21 copies as high-risk cytogenetic aber-(RRMM) are emerging and evolving rapidly. 1 rations (HRCAs). Chinese authors sought to summarize and reviewTheinternationalstudyprovidedpatientswith the results of RRMM trials over the past 5 years.Isa-KRdinduction/consolidationandIsa-KR The goal was to provide a holistic overview andmaintenance. TE patients received high-dose mel-insights for practitioners in related fields and tophalan,whileTNEpatientsreceivedtwoaddi-provide additional ideas for clinical trialists. tional Isa-KRd cycles postinduction. The prespeci-The study indicated that daratumumab and isatux- fied interim analysis (IA) reported the primary end imab continue to significantly advance as treatmentpoint,MRDnegativity(10-5,next-generation options. Additionally, novel antibody drugs, suchflow), at the end of consolidation. The secondary as elotuzumab and selinexor, as well as bispecificend point was progression-free survival (PFS).antibodies, teclistamab and talquetamab, are cur- The results indicated that, among 125 patients rently undergoing clinical research with promisingwith HRNDMM (TE-intention-to-treat [ITT]-IA, outcomes, according to the authors. However,99;TNE-ITT,26)oftheIApopulationfor chimericantigenreceptor-Tcelltherapytarget- theprimaryendpoint,themedianagewas58 ing B-cell maturation antigen remains the optimal(TE-ITT-IA) and 74 (TNE-ITT) years. Del17p was approach for MM treatment. the most common high-risk cytogenetic abnormal-Anotherrecenttrial,GMMG-CONCEPT,ity(HRCA),(TE,44.4%;TNE,42.3%);about investigatedisatuximab,carfilzomib,lenalido- one-third of evaluable TE/TNE patients presented mideanddexamethasone(Isa-KRd)intrans- two or more HRCAs, respectively. plant-eligible(TE)andtransplant-noneligibleThe trial met its primary end point with MRD (TNE) patients with newly diagnosed multiplenegativity rates after consolidation of 67.7% (TE) myeloma (NDMM). The study, reported in theand54.2%(TNE)ofpatients.Theresearchers JournalofClinicalOncology,wasfocusedadvised that 81 of 99 TE-ITT-IA patients reached 21'